Institution · Research Advocacy Network
Most cited papers from Research Advocacy Network
What are the most cited papers from Research Advocacy Network?
The most cited paper from Research Advocacy Network is "Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology" (William John Gradishar et al., 2020), with 1,628 citations. Next come "Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update" (1,132) and "Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology" (981).
Showing 50 of 77 papers. Every paper is listed.
| # | Paper | ||
|---|---|---|---|
| 1 | Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2020 | 1,628 |
| 2 | Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update Charles L. Loprinzi, Christina Lacchetti, Jonathan Scott Bleeker et al. · Journal of Clinical Oncology | 14 Jul 2020 | 1,132 |
| 3 | Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jun 2022 | 981 |
| 4 | Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jul 2024 | 653 |
| 5 | NCCN Guidelines Insights: Breast Cancer, Version 1.2017 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2017 | 545 |
| 6 | Breast Cancer Screening and Diagnosis, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology Therese Bartholomew Bevers et al. · Journal of the National Comprehensive Cancer Network | Nov 2018 | 526 |
| 7 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2023 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Jun 2023 | 461 |
| 8 | NCCN Guidelines® Insights: Breast Cancer, Version 4.2021 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | May 2021 | 352 |
| 9 | Composite grading algorithm for the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Ethan Basch, Claus C. Becker, Lauren J. Rogak et al. · Clinical Trials | Dec 2020 | 256 |
| 10 | Breast Cancer, Version 3.2018 Matthew Philip Goetz et al. · Journal of the National Comprehensive Cancer Network | Feb 2019 | 199 |
| 11 | Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy Amye Juliet Tevaarwerk, Robert J. Gray, Bryan Paul Schneider et al. · Cancer | 12 Oct 2012 | 196 |
| 12 | Breast Cancer Version 3.2014 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Apr 2014 | 185 |
| 13 | Genome-Wide Association Studies for Taxane-Induced Peripheral Neuropathy in ECOG-5103 and ECOG-1199 Bryan Paul Schneider et al. · Clinical Cancer Research | 3 Jul 2015 | 145 |
| 14 | NCCN Guidelines® Insights: Breast Cancer Screening and Diagnosis, Version 1.2023 Therese Bartholomew Bevers et al. · Journal of the National Comprehensive Cancer Network | Sep 2023 | 142 |
| 15 | Methods for Developing Patient-Reported Outcome-Based Performance Measures (PRO-PMs) Ethan Basch, John A. Spertus, R. Adams Dudley et al. · Value in Health | 21 May 2015 | 139 |
| 16 | Standardized Definitions for Efficacy End Points in Neoadjuvant Breast Cancer Clinical Trials: NeoSTEEP Jennifer Keating Litton et al. · Journal of Clinical Oncology | 11 Jul 2023 | 116 |
| 17 | Metastatic Breast Cancer, Version 1.2012 Robert W. Carlson et al. · Journal of the National Comprehensive Cancer Network | Jul 2012 | 116 |
| 18 | NCCN Guidelines® Insights: Breast Cancer, Version 5.2025 William John Gradishar et al. · Journal of the National Comprehensive Cancer Network | Nov 2025 | 80 |
| 19 | A Review of Zoonotic Disease Threats to Pet Owners: A Compendium of Measures to Prevent Zoonotic Diseases Associated with Non-Traditional Pets Such as Rodents and Other Small Mammals, Reptiles, Amphibians, Backyard Poultry, and Other Selected Animals Kate E. Varela, Jennifer Ann Brown, Beth A. Lipton et al. · Vector-Borne and Zoonotic Diseases | Jun 2022 | 76 |
| 20 | Targeted eHealth Intervention to Reduce Breast Cancer Survivors’ Fear of Recurrence: Results From the FoRtitude Randomized Trial Lynne I. Wagner, Janet Austin Tooze, Daniel L. Hall et al. · JNCI Journal of the National Cancer Institute | 29 May 2021 | 71 |
| 21 | Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial Nathaniel Sean O'Connell, Fengmin Zhao, Ju‐Whei Lee et al. · Journal of Clinical Oncology | 6 Oct 2023 | 48 |
| 22 | Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG‐ACRIN's Symptom Outcomes and Practice Patterns study Amye Juliet Tevaarwerk, Ju‐Whei Lee, Abigail Terhaar et al. · Cancer | 21 Dec 2015 | 48 |
| 23 | Genetic variant predicts bevacizumab-induced hypertension in ECOG-5103 and ECOG-2100 Bryan Paul Schneider et al. · British Journal of Cancer | 12 Aug 2014 | 44 |
| 24 | Patient-Reported Adverse Events and Early Treatment Discontinuation Among Patients With Multiple Myeloma John Devin Peipert, Fengmin Zhao, Ju‐Whei Lee et al. · JAMA Network Open | 27 Mar 2024 | 22 |
| 25 | Tumor Genomic Profiling Practices and Perceptions: A Survey of Physicians Participating in the NCI-MATCH Trial Alice P. Chen, Keith T. Flaherty, Peter James O'Dwyer et al. · JCO Precision Oncology | 5 Oct 2020 | 21 |
| 26 | Generating and evaluating evidence of the clinical utility of molecular diagnostic tests in oncology Patricia A. Deverka, Donna A. Messner, Robert Thomas Mccormack et al. · Genetics in Medicine | 3 Dec 2015 | 20 |
| 27 | Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment Kathleen Marie Beusterien, Martine C. Maculaitis, Bernadette Hallissey et al. · Patient Preference and Adherence | Mar 2021 | 19 |
| 28 | The Density Conundrum: Does Legislation Help or Hurt? Mary Lou Smith · Journal of the American College of Radiology | 29 Nov 2013 | 19 |
| 29 | Examining and predicting drug preferences of patients with metastatic breast cancer: using conjoint analysis to examine attributes of paclitaxel and capecitabine Mary Lou Smith, Carol White, Elda Railey et al. · Breast Cancer Research and Treatment | 20 Mar 2014 | 19 |
| 30 | Development and refinement of FoRtitude: An eHealth intervention to reduce fear of recurrence among breast cancer survivors Lynne I. Wagner, Jenna Duffecy, Mark J. Begale et al. · Psycho-Oncology | 24 Nov 2019 | 17 |
| 31 | Involving Advocates in Cancer Research Jane Perlmutter, Nancy Roach, Mary Lou Smith · Seminars in Oncology | 10 Jul 2015 | 17 |
| 32 | Facilitators and barriers to reducing chemotherapy for early-stage breast cancer: a qualitative analysis of interviews with patients and patient advocates Courtney J. Andrews, Timothy C. Childers, Kimberly D. Wiseman et al. · BMC Cancer | 4 Feb 2022 | 16 |
| 33 | Performance Measures Based on How Adults With Cancer Feel and Function: Stakeholder Recommendations and Feasibility Testing in Six Cancer Centers Angela M. Stover et al. · JCO Oncology Practice | 19 Feb 2020 | 16 |
| 34 | Patient familiarity with, understanding of, and preferences for clinical trial endpoints and terminology Mitchell S. von Itzstein, Elda Railey, Mary Lou Smith et al. · Cancer | 22 Jan 2020 | 16 |
| 35 | Oncologist-Reported Barriers and Facilitators to Enrolling Patients in Optimization Trials That Test Less Intense Cancer Treatment Gabrielle Betty Rocque, Courtney J. Andrews, Valerie M. Lawhon et al. · JCO Oncology Practice | 6 Dec 2022 | 13 |
| 36 | A spotlight on avoidance coping to manage fear of recurrence among breast cancer survivors in an eHealth intervention Daniel L. Hall, Beverly J. Levine, Elizabeth Jeter et al. · Journal of Behavioral Medicine | 5 Aug 2022 | 13 |
| 37 | Discerning the clinical relevance of biomarkers in early stage breast cancer Tarah Jean Ballinger, Nawal Kassem, Fei Shen et al. · Breast Cancer Research and Treatment | 11 Apr 2017 | 13 |
| 38 | Issues Surrounding Biospecimen Collection and Use in Clinical Trials Allison R. Baer, Mary Lou Smith, Deborah E. Collyar et al. · Journal of Oncology Practice | Jul 2010 | 12 |
| 39 | A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib Imtiaz A. Samjoo, Alexandra Hall, Connie Chen et al. · Journal of Comparative Effectiveness Research | 17 Sep 2024 | 11 |
| 40 | Reconsidering tolerability of cancer treatments: opportunities to focus on the patient John Devin Peipert, Mary Lou Smith, On Behalf Of the EVOLV Study Team · Supportive Care in Cancer | 11 Jan 2022 | 11 |
| 41 | Advocate-BREAST: advocates and patients’ advice to enhance breast cancer care delivery, patient experience and patient centered research by 2025 Ciara Catherine O'Sullivan, Nicole L. Larson, Robert Alan Vierkant et al. · Archives of Public Health | 7 Aug 2024 | 10 |
| 42 | Considering endpoints for comparative tolerability of cancer treatments using patient report given the estimand framework John Devin Peipert, Monique C. Breslin, Ethan Basch et al. · Journal of Biopharmaceutical Statistics | 15 Feb 2024 | 9 |
| 43 | Media reportage of suicide among police officers in Ghana: A mixed method analysis Collins Badu Agyemang, Feikoab Parimah · Cogent Social Sciences | 19 Oct 2022 | 9 |
| 44 | Redefining Quality Measurement in Cancer Care Elizabeth A. Nardi, James McCanney, Katy Winckworth-Prejsnar et al. · Journal of the National Comprehensive Cancer Network | May 2018 | 9 |
| 45 | Donating Tissue for Research: Patient and Provider Perspectives Allison R. Baer, Mary Lou Smith, Johanna C. Bendell · Journal of Oncology Practice | Sep 2011 | 8 |
| 46 | Natural Support for Canadians with Disabilities: A Scoping Review Julia Jansen-van Vuuren, Monique Nelson, Heather Plyley et al. · Canadian Journal of Disability Studies | 22 Apr 2024 | 7 |
| 47 | Patient preferences for CDK4/6 inhibitor treatments in HR+/HER2− early breast cancer: a discrete choice survey study Erica L. Mayer, Mary Lou Smith, Annie Guérin et al. · Breast Cancer Research and Treatment | 6 Feb 2025 | 7 |
| 48 | Accessing Targeted Therapies: A Potential Roadblock to Implementing Precision Oncology? Mitchell S. von Itzstein, Mary Lou Smith, Elda Railey et al. · JCO Oncology Practice | 10 May 2021 | 6 |
| 49 | Controversies in Breast Cancer Screening Strategies Therese Bartholomew Bevers, Kirsten B. Bibbins-Domingo, Kevin Charles Oeffinger et al. · Journal of the National Comprehensive Cancer Network | May 2016 | 6 |
| 50 | Infrastructure to Support Accrual of Older Adults to National Cancer Institute Clinical Trials Gretchen Genevieve Kimmick, Mina S. Sedrak, Grant Richard Williams et al. · JNCI Monographs | Dec 2022 | 5 |
Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.